Evidence analysisNovember 18, 2026Evidence
Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2025

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
Antimicrobial Resistance Trends in the EU/EEA: Evidence from the 2025 EARS-Net Report
What is established
Antimicrobial resistance (AMR) remains a significant public health concern within the European Union and European Economic Area (EU/EEA). The 2025 Annual Epidemiological Report by the European Centre for Disease Prevention and Control (ECDC), based on data from the European Antimicrobial Resistance Surveillance Network (EARS-Net), documents ongoing patterns in resistance among key bacterial pathogens causing bloodstream infections.
Notably, the report provides incidence estimates for three critical resistant infections: meticillin-resistant Staphylococcus aureus (MRSA), third-generation cephalosporin-resistant Escherichia coli (3GC-resistant E. coli), and carbapenem-resistant Klebsiella pneumoniae (CR K. pneumoniae). These data are essential for assessing progress towards EU targets on reducing AMR-associated infections by 2030.
What the source claims
- MRSA bloodstream infections: The 2025 estimated incidence in the EU/EEA is 4.56 cases per 100,000 population, representing a 19% decrease compared to 2019. This figure is slightly below the EU target of 4.79 cases per 100,000 for 2030, indicating progress in reducing MRSA infections. A statistically significant downward trend was observed between 2019 and 2025, although incidence has increased somewhat in the last two years.
- Third-generation cephalosporin-resistant E. coli bloodstream infections: The incidence was 12.13 cases per 100,000, which is 16.4% higher than in 2019 and above the 2030 target of 9.38 per 100,000. The data show no statistically significant trend overall from 2019 to 2025, yet incidence remained elevated during the last two years relative to baseline.
- Carbapenem-resistant K. pneumoniae bloodstream infections: Incidence rose sharply to 3.75 cases per 100,000 population in 2025, a 72% increase from 2019 and exceeding the 2030 target of 2.07 per 100,000 by a substantial margin. This trend was statistically significant, indicating worsening resistance levels in this critical pathogen.
In summary, while the EU target related to MRSA bloodstream infections appears to have been met ahead of schedule, progress for resistant E. coli and K. pneumoniae infections is absent or negative, with substantial increases that deviate from the goals set for 2030.
What may be missing from the usual framing
The publicly summarized data and the EU targets largely focus on incidence rates of bloodstream infections caused by specific resistant bacterial strains. This approach may omit other clinically relevant infections or resistance mechanisms that do not manifest primarily in bloodstream infections but still contribute to patient morbidity, healthcare costs, or community impacts.
Furthermore, the report highlights aggregate EU/EEA figures and country ranges but may not fully capture the heterogeneity of local healthcare systems, antibiotic stewardship policies, and infection control practices that influence resistance patterns. Variability in surveillance intensity, clinical diagnostics, and laboratory methods across countries can also affect the comparability of data.
There is limited explicit discussion in the summary about the impact of antimicrobial consumption patterns, public health interventions, or socioeconomic determinants, which are known drivers of resistance development. Additionally, the role of non-human antibiotic use (e.g., agriculture) and environmental factors is not elaborated, though these are increasingly recognized as important in the One Health framework.
Competing evidence or uncertainty
The source is a high-quality, authoritative surveillance report produced by the ECDC, relying on robust data collection from EU/EEA member states. However, there are inherent limitations typical of surveillance data including potential under-reporting, diagnostic and laboratory variability, and changes in healthcare-seeking behavior that might influence trends.
The observed increase in carbapenem-resistant K. pneumoniae and cephalosporin-resistant E. coli infections contrasts with the success seen in reducing MRSA. This divergence may stem from differing biological, ecological, or clinical factors influencing these pathogens. External studies have suggested that while MRSA control programs in hospitals and communities have been effective, the drivers for resistance in Enterobacterales (which include E. coli and K. pneumoniae) are more complex and may be influenced by broader issues such as antibiotic consumption in outpatient settings.
There may also be differences in definitions and detection methods for resistance that could affect trend interpretation. Not all European countries report uniformly, and some may have different capacities for detection and reporting of resistant bacteria.
While no specific counter-evidence to the observed trends is immediately apparent, independent verification and complementary studies would be necessary to confirm the generalizability and contextualize these findings internationally.
Why it matters
Antimicrobial resistance is recognized globally as a major threat to modern medicine, complicating the treatment of infections and increasing morbidity, mortality, and healthcare costs. The documented trends in the EU/EEA show mixed progress and highlight areas of concern that require urgent attention.
Reduction of MRSA bloodstream infections demonstrates that coordinated interventions and infection control measures can be effective. However, the increase in resistant Gram-negative infections such as cephalosporin-resistant E. coli and carbapenem-resistant K. pneumoniae illustrates that new or reinforced strategies may be needed to address these emerging challenges.
Failure to control these resistant infections threatens patient safety, limits therapeutic options, and may increase the incidence of sepsis and other severe complications. Since resistant pathogens can spread rapidly across borders, consistent surveillance, prevention, and prudent antibiotic use remain critical public health priorities.
What to verify next
- Examine the full 2025 EARS-Net Annual Epidemiological Report directly to assess detailed methodology, country-specific data, and additional context.
- Review associated reports on antimicrobial consumption to understand correlations between antibiotic use and resistance trends.
- Investigate whether novel diagnostic technologies, reporting standards, or clinical guidelines may have influenced surveillance data or interpretation.
- Explore independent research evaluating intervention effectiveness for cephalosporin- and carbapenem-resistant infections in EU/EEA healthcare settings.
- Assess One Health approaches regarding agricultural antibiotic use and environmental reservoirs of resistance to fill gaps beyond human clinical surveillance.
As antimicrobial resistance evolves and public health responses adapt, ongoing monitoring and critical appraisal of evidence sources remain essential. Readers should consult the original detailed report and related scientific publications to gain a comprehensive understanding of the current AMR landscape in Europe.
Source & verification
Primary source: Scientific and technical publications · November 18, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

EudraGMDP database
What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…

Rapid risk assessment – Carbapenem-resistant Enterobacterales, fourth update
Evidence Dossier: Carbapenem-resistant Enterobacterales (CRE) in the EU/EEA – Latest Scientific Assessment What is established Carbapenem-resistant Enterobacterales (CRE), which include bacteria such as Klebsiella…

European Antibiotic Awareness Day (EAAD): Media toolkit
What is established Antimicrobial resistance (AMR) is a growing public health concern in Europe and worldwide. It occurs when bacteria and other microorganisms develop…